PROVECTUS BIOPHARMS - PVCT STOCK NEWS

Provectus Biopharmaceuticals (OTCQB: PVCT) has scheduled its Fourth Quarter 2024 Investor Update webinar via Zoom for Thursday, November 14, 2024, at 2 p.m. EST. Interested participants can access the conference call by registering in advance through the provided Zoom registration link.

Provectus Biopharmaceuticals (OTCQB: PVCT) has announced a conference call scheduled for Thursday, November 14, 2024 at 2 p.m. EST. The purpose of the call is to provide Company updates. Provectus has stated that the conference call details will be shared closer to the event date. This announcement indicates that the company is planning to communicate important information to its stakeholders, which could potentially include updates on financial performance, research and development progress, or other significant business developments.

Provectus Biopharmaceuticals announced an investor webinar for its 2024 annual stockholder meeting. The meeting will take place on June 20, 2024, at the Hilton Knoxville and will also be accessible via Zoom Webinar. Only stockholders of record as of April 24, 2024, may vote at the meeting by attending in person or through proxy materials. While the webinar provides an update and meeting activities overview, it does not count for quorum or voting purposes. Proxy materials and the 2023 Annual Report are available on the company's website and the SEC's website.

Provectus Biopharmaceuticals announced non-clinical data on its rose bengal sodium (RBS) for treating full-thickness cutaneous wounds at the Society for Investigative Dermatology (SID) 2024 Annual Meeting. The study, led by Dr. Amina El Ayadi at the University of Texas Medical Branch, revealed that RBS treatment accelerated wound closure, reduced transepidermal water loss, increased collagen density, and improved vascularity with no toxicity or adverse effects. These findings suggest that RBS could enhance wound healing and prevent fibrosis, making it a promising treatment for severe skin wounds.

Provectus Biopharmaceuticals (OTCQB: PVCT) announced clinical and non-clinical data presentations on rose bengal photodynamic antimicrobial therapy (RB PDAT) at the ARVO 2024 Annual Meeting held May 5-9 in Seattle. The company has entered an exclusive worldwide license agreement with the University of Miami to commercialize RB PDAT for treating various eye infections. They plan to form a start-up, Eyecare NewCo, by Q3 2024. Presentations covered diverse aspects of RB PDAT, including safety and effectiveness. RB PDAT is currently in two Phase 3 trials and has been used in the U.S., India, Brazil, and Mexico.

Provectus Biopharmaceuticals, Inc. announced the allowance of a U.S. patent for the oral administration of Rose Bengal Sodium in treating hematologic cancers, including leukemia. The patent covers the use of Provectus's pharmaceutical grade RBS for therapy in pediatric and adult leukemias. This marks a significant development in the company's patent portfolio, showcasing their commitment to innovation and potential in cancer treatment.

Provectus Biopharmaceuticals announced the publication of preclinical data on the oral administration of Provectus Rose Bengal for solid tumor cancers. The research focused on breast, colorectal, head and neck, and testicular cancers, highlighting novel downregulation of WNK1 and Wnt signaling. The University of Calgary conducted the preclinical research, demonstrating the efficacy of Provectus's rose bengal in adult solid tumors. The findings suggest potential broader applications for treating solid tumor cancers.

Provectus Biopharmaceuticals appoints Ed Pershing as CEO and Dominic Rodrigues as President, emphasizing commitment to shareholder value. Pershing brings extensive healthcare consulting experience, while Rodrigues has a background in management consulting and corporate development. The company aims to develop innovative immunotherapy medicines and enhance investor communications.

Provectus Biopharmaceuticals, Inc. announced significant anti-tumor activity of PV-10 in head and neck cancers based on preclinical research by Moffitt Cancer Center. The research demonstrated PV-10's effectiveness in inducing immunogenic cell death and tumor regression in HPV-positive and HPV-negative head and neck squamous cell carcinoma.